The natural history of dysplasia and cancer in esophagitis and Barrett esophagus

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The natural history of metaplasia and dysplasia in Barrett esophagus is not well defined. Publication bias, the selective reporting of studies that have positive or extreme results, has exaggerated the risk of esophageal adenocarcinoma in this condition. Recent data suggest that patients with Barrett esophagus develop these tumors at the rate of 0.5% per year, a cancer incidence considerably lower than was appreciated just a few years ago. Indirect evidence suggests that aggressive treatment of gastroesophageal reflux might decrease the risk of carcinogenesis, but no therapy yet has been proved to decrease the incidence of cancer in Barrett esophagus. Dysplasia in the metaplastic epithelium clearly is a worrisome finding, but the progression from dysplasia to cancer may take years and may not be inevitable.

Original languageEnglish (US)
JournalJournal of Clinical Gastroenterology
Volume36
Issue number5 SUPPL.
DOIs
StatePublished - May 2003

Fingerprint

Barrett Esophagus
Esophagitis
Natural History
Neoplasms
Publication Bias
Incidence
Metaplasia
Gastroesophageal Reflux
Carcinogenesis
Adenocarcinoma
Epithelium
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The natural history of dysplasia and cancer in esophagitis and Barrett esophagus. / Spechler, Stuart Jon.

In: Journal of Clinical Gastroenterology, Vol. 36, No. 5 SUPPL., 05.2003.

Research output: Contribution to journalArticle

@article{17c4eb6a06f546dca4c5feaa8656b6a0,
title = "The natural history of dysplasia and cancer in esophagitis and Barrett esophagus",
abstract = "The natural history of metaplasia and dysplasia in Barrett esophagus is not well defined. Publication bias, the selective reporting of studies that have positive or extreme results, has exaggerated the risk of esophageal adenocarcinoma in this condition. Recent data suggest that patients with Barrett esophagus develop these tumors at the rate of 0.5{\%} per year, a cancer incidence considerably lower than was appreciated just a few years ago. Indirect evidence suggests that aggressive treatment of gastroesophageal reflux might decrease the risk of carcinogenesis, but no therapy yet has been proved to decrease the incidence of cancer in Barrett esophagus. Dysplasia in the metaplastic epithelium clearly is a worrisome finding, but the progression from dysplasia to cancer may take years and may not be inevitable.",
author = "Spechler, {Stuart Jon}",
year = "2003",
month = "5",
doi = "10.1097/00004836-200305001-00002",
language = "English (US)",
volume = "36",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "5 SUPPL.",

}

TY - JOUR

T1 - The natural history of dysplasia and cancer in esophagitis and Barrett esophagus

AU - Spechler, Stuart Jon

PY - 2003/5

Y1 - 2003/5

N2 - The natural history of metaplasia and dysplasia in Barrett esophagus is not well defined. Publication bias, the selective reporting of studies that have positive or extreme results, has exaggerated the risk of esophageal adenocarcinoma in this condition. Recent data suggest that patients with Barrett esophagus develop these tumors at the rate of 0.5% per year, a cancer incidence considerably lower than was appreciated just a few years ago. Indirect evidence suggests that aggressive treatment of gastroesophageal reflux might decrease the risk of carcinogenesis, but no therapy yet has been proved to decrease the incidence of cancer in Barrett esophagus. Dysplasia in the metaplastic epithelium clearly is a worrisome finding, but the progression from dysplasia to cancer may take years and may not be inevitable.

AB - The natural history of metaplasia and dysplasia in Barrett esophagus is not well defined. Publication bias, the selective reporting of studies that have positive or extreme results, has exaggerated the risk of esophageal adenocarcinoma in this condition. Recent data suggest that patients with Barrett esophagus develop these tumors at the rate of 0.5% per year, a cancer incidence considerably lower than was appreciated just a few years ago. Indirect evidence suggests that aggressive treatment of gastroesophageal reflux might decrease the risk of carcinogenesis, but no therapy yet has been proved to decrease the incidence of cancer in Barrett esophagus. Dysplasia in the metaplastic epithelium clearly is a worrisome finding, but the progression from dysplasia to cancer may take years and may not be inevitable.

UR - http://www.scopus.com/inward/record.url?scp=0037405661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037405661&partnerID=8YFLogxK

U2 - 10.1097/00004836-200305001-00002

DO - 10.1097/00004836-200305001-00002

M3 - Article

VL - 36

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 5 SUPPL.

ER -